Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05

Envista Holdings Corp

2024-FY EPS reported -$6.50 revenue$2,510,600,000

Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.
Full-year 2024 net loss $1.12B (incl. impairment), adjusted net income $127M vs $269M in 2023.
Free cash flow $124M in Q4, up 24% YoY; operating cash flow $132M, up 30%.
Implants improved with growth in Nobel Biocare, Implant Direct, Alpha-Bio; Spark aligners gained share and gross margin.
FY2025 guidance: core sales growth 1-3%, adjusted EBITDA margin ~14%, adjusted EPS $0.95-$1.05.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.